Will This Price Target Increase Help AstraZeneca (AZN) Stock Today? (Update)

Update (9:38 a.m.): Updated with Wednesday market open information.

NEW YORK ( TheStreet) --  Barclays increased its price target on  AstraZeneca  ( AZN) to $40, increased its estimates and set an "equal weight" rating. Contribution from pipeline products to push sales growth drove the firm's decision.

The stock was up 2.91% to $74.30 at 9:37 a.m. on Wednesday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AZN Chart

AZN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

AstraZeneca Stock Gains as Crestor Sales Decline Slows

AstraZeneca Stock Gains as Crestor Sales Decline Slows

FDA Approves AstraZeneca's Blood Cancer Drug

FDA Approves AstraZeneca's Blood Cancer Drug